Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial PR Newswire RADNOR, Pa. and GENEVA , Jan. 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding ...
NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure PR Newswire RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEU...
GENEVA, SWITZERLAND / ACCESSWIRE / December 21, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today a...
GENEVA, SWITZERLAND / ACCESSWIRE / December 18, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, announc...
Speaking to CNBC, Relief Therapeutics' ([[RLFTF]] +11.5%) Chairman Ram Selvaraju said the ongoing Phase 2b/3 trial with RLF-100 is expected to provide topline data in 1H of January, and attributed the 38,000% rise so far this year, in share price in part to its evidence of efficacy ...
NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure RADNOR, Pa. and GENEVA, Dec. 7, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX...
Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients. In ...
Correction of the press release published November 24, 2020: It has come to our attention that a mistake was printed in the percentage of control patients in the EAP who survived to day 28. The correct percentage is 27%, not 17% of the control patients, all treated with best available intens...
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients PR Newswire RADNOR, Pa. and GENEVA, Nov. 24, 2020 RADNOR, Pa....
Relief Therapeutics (RLFTF) and NeuroRx announce that more than 175 patients with Critical COVID-19 and Respiratory Failure have now been entered into an Expanded Access Protocol ((EAP)) with RLF-100 in the U.S. All patients had severe comorbidities (such as organ transplant, recent heart att...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...